Entera Bio Ltd.
ENTX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001638097
No open-market purchases or sales by Entera Bio Ltd. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $19.0M in total; no superinvestor holds it.
Q1 2022 vs. Q4 2021
How the institutions holding Entera Bio Ltd. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 12 | 12 | 0 |
| Shares | 5.66M | 4.95M | −706.1K (−12.5%) |
| Value | $15.9M | $14.2M | −$1.72M (−10.8%) |
New holders (4)
Institutions that held Entera Bio Ltd. at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Millennium Management LLC | 46,209 | $132.0K | 0.00% |
| The PNC Financial Services Group, Inc. | 10,000 | $29.0K | 0.00% |
| UBS Group AG | 4,660 | $13.0K | 0.00% |
| Royal Bank of Canada | 581 | $2.00K | 0.00% |
Sold out (4)
Institutions that held Entera Bio Ltd. at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Renaissance Technologies LLC | 40,100 | $113.0K |
| Bank of America Corp | 13,866 | $39.0K |
| Susquehanna Fundamental Investments, LLC | 10,200 | $29.0K |
| JPMorgan Chase & Co | 2 | $0 |